Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, a treatment for multiple myeloma, a rare type of blood cancer. Their study, “Predictors of Response to Venetoclax and Therapeutic Potential of CDK7 Inhibition in Multiple Myeloma,” was published this month in the journal Blood Neoplasia.
Medical Xpress – latest medical and health news stories
